University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
David Abram Solomon, MD, PhD

David Abram Solomon, MD, PhD

Clinical Fellow, Department of Pathology, UCSF

Cancer Center Program Memberships

Cancer Genetics

Research Summary

Starting early in my education, I have been very interested in complex biological systems with relevance to human disease. During my four years at the College of William & Mary, I performed research in the lab of Dr. Margaret Saha defining the spatiotemporal development of neurotransmitter systems within the amphibian brain. I spent my summers during my undergraduate training in the multiple sclerosis lab of Dr. Timothy Vartanian at Harvard Medical School studying the regulation of oligodendrocyte myelination in the developing central nervous system. After completion of my undergraduate degree, I worked for two years at the University of Cincinnati College of Medicine in the lab of Dr. Erik Knudsen studying the regulation of cell growth by the retinoblastoma tumor suppressor, which led to several first-author publications, the most prominent of which describes the discovery of a novel oncogenic splice variant of cyclin D1 which we termed cyclin D1b and published in the Journal of Biological Chemistry in 2003.

Thereafter, I completed my medical and graduate training in the MD/PhD program at Georgetown University School of Medicine with my thesis research “Identification and Therapeutic Targeting of Novel Transforming Pathways in Human Glioblastoma Multiforme” performed in the lab of Dr. Todd Waldman. During my time at Georgetown, I gained expertise in the genetics of brain tumors and sought an opportunity to apply this knowledge in the field of diagnostic and translational neuropathology. I then entered a combined Anatomic Pathology Residency and Neuropathology Fellowship at UCSF, where I am currently in the final year of training devoted to neuropathology research with minimal clinical responsibilities. I am very interested in the application of molecular diagnostics for cancer pathology and the use of personalized targeted therapeutics based on the genetic profile of individual tumor specimens. I aspire to be an academic physician-scientist both attending as a neuropathologist and molecular pathologist, as well as continuing my research on the genetics of cancer.

During my graduate training, I made an important discovery in the field of cancer biology by identifying mutational inactivation of the STAG2 gene as one of the first common genetic causes of aneuploidy in human cancer (Solomon et al., Science, 2011). Moreover, I have subsequently discovered frequent truncating mutations of this cohesin complex gene STAG2 in urothelial bladder carcinoma (Solomon et al., Nature Genetics, 2013) and Ewing’s sarcoma (Brohl and Solomon et al., PLoS Genetics, 2014) which define a molecular subgroup of these tumors with distinct clinical outcomes. I now aim to define the role of cohesin gene inactivation in cancer pathogenesis and develop effective targeted therapies for the many patients whose tumors harbor cohesin mutations.

Education

College of William and Mary, Williamsburg, VA B.S., 2002, Molecular Cell Biology
University of Cincinnati College of Medicine, OH post-bac research, 2004, Cancer Biology
Georgetown University, Washington, DC, M.D., Ph.D. 08/04-05/12 Medicine, Tumor Biology
University of California, San Francisco, CA, Residency 07/12-06/14 Anatomic Pathology
University of California, San Francisco, CA, Fellowship 07/14-06/16 Neuropathology


Professional Experience

  • 07/2016
    Assistant Professor, Department of Pathology, University of California, San Francisco

Honors & Awards

  • 2015-2020
    NIH Director’s Early Independence Award, funded from the NIH Common Fund's High-Risk, High-Reward Program to support early independence of exceptional early career scientists
  • 2015-2016
    Career Development Research Award, UCSF Brain Tumor SPORE
  • 2015
    Hans Popper Hepatopathology Society Award, best abstract presentation by a trainee at the 2015 United States & Canada Academy of Pathology Annual Meeting, Boston
  • 2014
    Stowell-Orbison Award, one of three recipients of award presented at the 2014 U.S. & Canada Academy of Pathology Annual Meeting for best abstract presentation by a trainee, San Diego
  • 2014
    International Society of Bone & Soft Tissue Pathology Young Investigator Award, best abstract presentation by a trainee at the 2014 U.S. & Canada Academy of Pathology Annual Meeting
  • 2013
    Outstanding Resident Research Award, recipient of annual award from The Resident Research Training Program, UCSF
  • 2013
    Julius R. Krevans Award, recipient of annual award presented for clinical excellence to a UCSF intern in each specialty at San Francisco General Hospital
  • 2013
    Stowell-Orbison Award, one of four recipients of award presented at the 2013 U.S. & Canada Academy of Pathology Annual Meeting for best abstract presentation by a trainee, Baltimore
  • 2012
    Harold Weintraub Graduate Student Award, one of twelve recipients of award presented at the 2012 Weintraub Memorial Symposium at the Fred Hutchinson Cancer Research Center, Seattle
  • 2012
    Future Leaders in Basic Cancer Research, one of four recipients of award presented at the 2012 American Association for Cancer Research Annual Meeting, Chicago

Selected Publications

  1. Hayes J, Yu Y, Jalbert LE, Mazor T, Jones LE, Wood MD, Walsh KM, Bengtsson H, Hong C, Oberndorfer S, Roetzer T, Smirnov IV, Clarke JL, Aghi MK, Chang SM, Nelson SJ, Woehrer A, Phillips JJ, Solomon DA, Costello JF. Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro Oncol. 2018 Apr 09; 20(5):632-641.
    View on PubMed
  2. Goode B, Mondal G, Hyun M, Ruiz DG, Lin YH, Van Ziffle J, Joseph NM, Onodera C, Talevich E, Grenert JP, Hewedi IH, Snuderl M, Brat DJ, Kleinschmidt-DeMasters BK, Rodriguez FJ, Louis DN, Yong WH, Lopes MB, Rosenblum MK, Butowski N, Tihan T, Bollen AW, Phillips JJ, Wiita AP, Yeh I, Jacobson MP, Bastian BC, Perry A, Solomon DA. A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nat Commun. 2018 02 23; 9(1):810.
    View on PubMed
  3. Iorgulescu JB, Van Ziffle J, Stevers M, Grenert JP, Bastian BC, Chavez L, Stichel D, Buchhalter I, Samuel D, Nicolaides T, Banerjee A, Mueller S, Gupta N, Tihan T, Bollen AW, Northcott PA, Kool M, Pfister S, Korshunov A, Perry A, Solomon DA. Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathol. 2018 Apr; 135(4):635-638.
    View on PubMed
  4. Pekmezci M, Stevers M, Phillips JJ, Van Ziffle J, Bastian BC, Tsankova NM, Kleinschmidt-DeMasters BK, Rosenblum MK, Tihan T, Perry A, Solomon DA. Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway. Acta Neuropathol. 2018 Mar; 135(3):485-488.
    View on PubMed
  5. Paret C, Russo A, Otto H, Mayer A, Zahnreich S, Wagner W, Samuel D, Scharnhorst D, Solomon DA, Dhall G, Wong K, Bender H, Alt F, Wingerter A, Neu MA, Beck O, Prawitt D, Eder S, Henninger N, El Malki K, Lehmann N, Backes N, Roth L, Seidmann L, Sommer C, Brockmann MA, Staatz G, Schmidberger H, Faber J. Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy. Oncotarget. 2017 Dec 26; 8(69):114210-114225.
    View on PubMed
  6. Goode B, Joseph NM, Stevers M, Van Ziffle J, Onodera C, Talevich E, Grenert JP, Yeh I, Bastian BC, Phillips JJ, Garg K, Rabban JT, Zaloudek C, Solomon DA. Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Mod Pathol. 2017 Nov 17.
    View on PubMed
  7. Wood MD, Tihan T, Perry A, Chacko G, Turner C, Pu C, Payne C, Yu A, Bannykh SI, Solomon DA. Multimodal molecular analysis of astroblastoma enables reclassification of most cases into more specific molecular entities. Brain Pathol. 2018 03; 28(2):192-202.
    View on PubMed
  8. Lopez GY, Oberheim Bush NA, Phillips JJ, Bouffard JP, Moshel YA, Jaeckle K, Kleinschmidt-DeMasters BK, Rosenblum MK, Perry A, Solomon DA. Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression. Acta Neuropathol. 2017 Dec; 134(6):961-963.
    View on PubMed
  9. Chan AK, Han SJ, Choy W, Beleford D, Aghi MK, Berger MS, Shieh JT, Bollen AW, Perry A, Phillips JJ, Butowski N, Solomon DA. Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. Clin Neuropathol. 2017 Sep/Oct; 36(5):213-221.
    View on PubMed
  10. Graham RP, Yeh MM, Lam-Himlin D, Roberts LR, Terracciano L, Cruise MW, Greipp PT, Zreik RT, Jain D, Zaid N, Salaria SN, Jin L, Wang X, Rustin JG, Kerr SE, Sukov WR, Solomon DA, Kakar S, Waterhouse E, Gill RM, Ferrell L, Alves VA, Nart D, Yilmaz F, Roessler S, Longerich T, Schirmacher P, Torbenson MS. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. Mod Pathol. 2018 Jan; 31(1):141-149.
    View on PubMed
  11. Chan E, Bollen AW, Sirohi D, Van Ziffle J, Grenert JP, Kline CN, Tihan T, Perry A, Gupta N, Solomon DA. Angiocentric glioma with MYB-QKI fusion located in the brainstem, rather than cerebral cortex. Acta Neuropathol. 2017 Oct; 134(4):671-673.
    View on PubMed
  12. Sorge C, Li R, Singh S, Reddy AT, Solomon DA, Perry A, Friedman GK. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. Pediatr Blood Cancer. 2017 Dec; 64(12).
    View on PubMed
  13. Ferris SP, Hofmann JW, Solomon DA, Perry A. Characterization of gliomas: from morphology to molecules. Virchows Arch. 2017 Aug; 471(2):257-269.
    View on PubMed
  14. Dahlin LB, Scherman P, Besjakov J, Lindberg E, Solomon DA, Horvai AE, Perry A. Intraneural glomus tumor of "uncertain malignant potential" and with BRAF mutation in the median nerve - an unusual case. Clin Neuropathol. 2017 Jul/Aug; 36(4):164-170.
    View on PubMed
  15. Krings G, Joseph NM, Bean GR, Solomon D, Onodera C, Talevich E, Yeh I, Grenert JP, Hosfield E, Crawford ED, Jordan RC, van Zante A, Zaloudek C, Shin SJ, Chen YY. Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. Mod Pathol. 2017 Aug; 30(8):1086-1099.
    View on PubMed
  16. López G, Oberheim Bush NA, Berger MS, Perry A, Solomon DA. Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma. Acta Neuropathol Commun. 2017 05 15; 5(1):38.
    View on PubMed
  17. Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein S, Torkildson J, Samuel D, Bloomer M, Campomanes AGA, Banerjee A, Butowski N, Raffel C, Tihan T, Bollen AW, Phillips JJ, Korn WM, Yeh I, Bastian BC, Gupta N, Mueller S, Perry A, Nicolaides T, Solomon DA. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro Oncol. 2017 05 01; 19(5):699-709.
    View on PubMed
  18. Erwood AA, Velazquez-Vega JE, Neill S, Solomon DA, Butowski N, Nowlan A, Dunbar E, Brat DJ. Chordoid glioma of the third ventricle: report of a rapidly progressive case. J Neurooncol. 2017 May; 132(3):487-495.
    View on PubMed
  19. Cuevas-Ocampo AK, Bollen AW, Goode B, Pajtler KW, Chavez L, Sharma T, Dai SC, McDermott M, Perry A, Korshunov A, Solomon DA. Genetic confirmation that ependymoma can arise as part of multiple endocrine neoplasia type 1 (MEN1) syndrome. Acta Neuropathol. 2017 04; 133(4):661-663.
    View on PubMed
  20. Aboian MS, Solomon DA, Felton E, Mabray MC, Villanueva-Meyer JE, Mueller S, Cha S. Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation. AJNR Am J Neuroradiol. 2017 Apr; 38(4):795-800.
    View on PubMed

Go to UCSF Profiles, powered by CTSI